Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data from clinical studies of the company’s
investigational, oral, once-daily, fixed-dose combination chronic
hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are
scheduled to be presented at the 65 th American Association
for the Study of Liver Diseases (AASLD) Annual Meeting, also known as
The Liver Meeting ® .
for Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting investment picks